These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

497 related items for PubMed ID: 16980998

  • 21. Engraftment syndrome after hematopoietic stem cell transplantation in multiple myeloma.
    Katzel JA, Mazumder A, Jagannath S, Vesole DH.
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):151. PubMed ID: 17026829
    [No Abstract] [Full Text] [Related]

  • 22. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
    Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R, Breitz H, Alexanian R, Champlin R, Giralt S.
    Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
    [Abstract] [Full Text] [Related]

  • 23. Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes.
    Chen CI, Abraham R, Tsang R, Crump M, Keating A, Stewart AK.
    Bone Marrow Transplant; 2001 Jan; 27(2):177-82. PubMed ID: 11281387
    [Abstract] [Full Text] [Related]

  • 24. Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
    Waśko-Grabowska A, Rzepecki P, Oborska S, Barzał J, Gawroński K, Młot B, Szczylik C.
    Transplant Proc; 2011 Oct; 43(8):3111-3. PubMed ID: 21996239
    [Abstract] [Full Text] [Related]

  • 25. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
    Fenk R, Schneider P, Kropff M, Huenerlituerkoglu AN, Steidl U, Aul C, Hildebrandt B, Haas R, Heyll A, Kobbe G, West German Myeloma Study Group.
    Br J Haematol; 2005 Aug; 130(4):588-94. PubMed ID: 16098074
    [Abstract] [Full Text] [Related]

  • 26. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.
    Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA.
    Bone Marrow Transplant; 2007 Mar; 39(5):279-83. PubMed ID: 17262062
    [Abstract] [Full Text] [Related]

  • 27. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage.
    Clopés A, Sureda A, Sierra J, Queraltó JM, Broto A, Farré R, Moreno E, Brunet S, Martino R, Mangues MA.
    Eur J Haematol; 2006 Jul; 77(1):1-6. PubMed ID: 16573745
    [Abstract] [Full Text] [Related]

  • 28. MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation.
    Mølle I, Peterslund NA, Thiel S, Steffensen R.
    Bone Marrow Transplant; 2006 Oct; 38(8):555-60. PubMed ID: 16953214
    [Abstract] [Full Text] [Related]

  • 29. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma.
    Moreau P, Milpied N, Mahé B, Juge-Morineau N, Rapp MJ, Bataille R, Harousseau JL.
    Bone Marrow Transplant; 1999 May; 23(10):1003-6. PubMed ID: 10373065
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
    Blimark C, Veskovski L, Westin J, Rödjer S, Brune M, Hjorth M, Holmberg E, Andersson PO, Mellqvist UH.
    Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Oral integrity and salivary profile in myeloma patients undergoing high-dose therapy followed by autologous SCT.
    Avivi I, Avraham S, Koren-Michowitz M, Zuckerman T, Aviv A, Ofran Y, Benyamini N, Nagler A, Rowe JM, Nagler RM.
    Bone Marrow Transplant; 2009 May; 43(10):801-6. PubMed ID: 19029961
    [Abstract] [Full Text] [Related]

  • 38. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Stella-Holowiecka B, Czerw T, Holowiecka-Goral A, Giebel S, Wojnar J, Holowiecki J.
    Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
    [Abstract] [Full Text] [Related]

  • 39. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.
    Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Tefferi A, Litzow MR.
    Bone Marrow Transplant; 2004 Dec; 34(12):1025-31. PubMed ID: 15516945
    [Abstract] [Full Text] [Related]

  • 40. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.
    Abidi MH, Agarwal R, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Ratanatharathorn V, Zonder J, Uberti J.
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):56-61. PubMed ID: 22892551
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.